Does the media prefer NRC or HCAT?

In the previous week, National Research had 8 more articles in the media than Health Catalyst. MarketBeat recorded 10 mentions for National Research and 2 mentions for Health Catalyst. National Research's average media sentiment score of 0.96 beat Health Catalyst's score of 0.89 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EVH or HCAT?

In the previous week, Evolent Health had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for Evolent Health and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat Evolent Health's score of 0.36 indicating that Health Catalyst is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HCAT or CTEV?

In the previous week, Health Catalyst had 1 more articles in the media than Claritev. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for Claritev. Health Catalyst's average media sentiment score of 0.89 beat Claritev's score of 0.38 indicating that Health Catalyst is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Claritev 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HCAT or AMWL?

In the previous week, American Well had 4 more articles in the media than Health Catalyst. MarketBeat recorded 6 mentions for American Well and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat American Well's score of 0.53 indicating that Health Catalyst is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive American Well 3 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPRX or HCAT?

In the previous week, OptimizeRx had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat OptimizeRx's score of 0.61 indicating that Health Catalyst is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Catalyst 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Health Catalyst (HCAT) Competitors

$1.74 -0.01 (-0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 -0.01 (-0.57%)

As of 06:20 PM Eastern

Compare

HCAT vs. NRC, EVH, CTEV, AMWL, and OPRX

Should you buy Health Catalyst stock or one of its competitors? Health Catalyst's main competitors and comparable companies include National Research (NRC), Evolent Health (EVH), Claritev (CTEV), American Well (AMWL), and OptimizeRx (OPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Health Catalyst compare to National Research?

National Research (NASDAQ:NRC) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, National Research had 8 more articles in the media than Health Catalyst. MarketBeat recorded 10 mentions for National Research and 2 mentions for Health Catalyst. National Research's average media sentiment score of 0.96 beat Health Catalyst's score of 0.89 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research has higher earnings, but lower revenue than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.38	$11.60M	$0.25	81.64
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

National Research has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

47.3% of National Research shares are owned by institutional investors. Comparatively, 85.0% of Health Catalyst shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 19.4% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

National Research presently has a consensus target price of $26.00, suggesting a potential upside of 27.39%. Health Catalyst has a consensus target price of $2.15, suggesting a potential upside of 22.86%. Given National Research's higher possible upside, equities research analysts plainly believe National Research is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Health Catalyst	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

National Research has a net margin of 4.18% compared to Health Catalyst's net margin of -90.61%. National Research's return on equity of 164.26% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Health Catalyst	-90.61%	-1.83%	-0.80%

Summary

National Research beats Health Catalyst on 10 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to Evolent Health?

Evolent Health (NYSE:EVH) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Evolent Health presently has a consensus price target of $5.96, indicating a potential upside of 40.83%. Health Catalyst has a consensus price target of $2.15, indicating a potential upside of 22.86%. Given Evolent Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evolent Health is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Health Catalyst	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Health Catalyst has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.26	-$534.51M	-$4.57	N/A
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

In the previous week, Evolent Health had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for Evolent Health and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat Evolent Health's score of 0.36 indicating that Health Catalyst is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolent Health has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Evolent Health has a net margin of -24.08% compared to Health Catalyst's net margin of -90.61%. Health Catalyst's return on equity of -1.83% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
Health Catalyst	-90.61%	-1.83%	-0.80%

85.0% of Health Catalyst shares are owned by institutional investors. 1.5% of Evolent Health shares are owned by insiders. Comparatively, 19.4% of Health Catalyst shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Health Catalyst beats Evolent Health on 10 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to Claritev?

Health Catalyst (NASDAQ:HCAT) and Claritev (NYSE:CTEV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Health Catalyst has higher earnings, but lower revenue than Claritev. Claritev is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
Claritev	$965.41M	0.43	-$284.28M	-$17.01	N/A

In the previous week, Health Catalyst had 1 more articles in the media than Claritev. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for Claritev. Health Catalyst's average media sentiment score of 0.89 beat Claritev's score of 0.38 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Claritev	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 87.2% of Claritev shares are held by institutional investors. 19.4% of Health Catalyst shares are held by company insiders. Comparatively, 7.4% of Claritev shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Health Catalyst has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Claritev has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Health Catalyst currently has a consensus target price of $2.15, suggesting a potential upside of 22.86%. Claritev has a consensus target price of $44.83, suggesting a potential upside of 83.67%. Given Claritev's stronger consensus rating and higher probable upside, analysts plainly believe Claritev is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Claritev	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Claritev has a net margin of -28.46% compared to Health Catalyst's net margin of -90.61%. Claritev's return on equity of 0.00% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
Claritev	-28.46%	N/A	-5.76%

Summary

Health Catalyst and Claritev tied by winning 8 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to American Well?

Health Catalyst (NASDAQ:HCAT) and American Well (NYSE:AMWL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

American Well has lower revenue, but higher earnings than Health Catalyst. American Well is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
American Well	$249.32M	0.82	-$95.70M	-$4.77	N/A

American Well has a net margin of -35.75% compared to Health Catalyst's net margin of -90.61%. Health Catalyst's return on equity of -1.83% beat American Well's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
American Well	-35.75%	-30.12%	-22.30%

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 12.8% of American Well shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Health Catalyst has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, American Well has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Health Catalyst presently has a consensus price target of $2.15, suggesting a potential upside of 22.86%. American Well has a consensus price target of $9.50, suggesting a potential downside of 23.41%. Given Health Catalyst's stronger consensus rating and higher possible upside, equities analysts clearly believe Health Catalyst is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
American Well	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, American Well had 4 more articles in the media than Health Catalyst. MarketBeat recorded 6 mentions for American Well and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat American Well's score of 0.53 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
American Well	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Health Catalyst beats American Well on 11 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to OptimizeRx?

OptimizeRx (NASDAQ:OPRX) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, OptimizeRx had 1 more articles in the media than Health Catalyst. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.89 beat OptimizeRx's score of 0.61 indicating that Health Catalyst is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has higher earnings, but lower revenue than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.42	$5.13M	$0.23	35.74
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 19.4% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OptimizeRx presently has a consensus target price of $11.57, indicating a potential upside of 40.77%. Health Catalyst has a consensus target price of $2.15, indicating a potential upside of 22.86%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Health Catalyst	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

OptimizeRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

OptimizeRx has a net margin of 4.66% compared to Health Catalyst's net margin of -90.61%. OptimizeRx's return on equity of 9.44% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Health Catalyst	-90.61%	-1.83%	-0.80%

Summary

OptimizeRx beats Health Catalyst on 11 of the 16 factors compared between the two stocks.

Get Health Catalyst News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCAT vs. The Competition

Export

Metric	Health Catalyst	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$131.70M	$1.88B	$7.27B	$13.21B
Dividend Yield	N/A	3.94%	2.52%	22.89%
P/E Ratio	N/A	15.32	177.90	18.12
Price / Sales	0.42	92.90	561.77	81.05
Price / Cash	0.82	32.13	77.16	53.04
Price / Book	0.50	6.04	10.71	6.03
Net Income	-$177.97M	-$19.09M	$3.50B	$380.34M
7 Day Performance	-1.69%	-1.43%	-3.18%	-3.04%
1 Month Performance	2.35%	-0.80%	-6.61%	-5.16%
1 Year Performance	-35.79%	-20.36%	3.69%	-2.48%

Health Catalyst Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCAT Health Catalyst	3.637 of 5 stars	$1.74 -0.6%	$2.15 +23.6%	-34.0%	$131.70M	$311.14M	N/A	1,200	High Trading Volume
NRC National Research	3.9197 of 5 stars	$20.23 -2.6%	$26.00 +28.5%	+77.8%	$460.61M	$140.00M	81.00	357
EVH Evolent Health	3.2983 of 5 stars	$3.78 +4.6%	$5.96 +58.0%	-46.9%	$427.93M	$1.88B	N/A	4,200	News Coverage
CTEV Claritev	2.9576 of 5 stars	$23.20 -6.0%	$44.83 +93.2%	-54.6%	$393.24M	$965.41M	N/A	3,000
AMWL American Well	2.0537 of 5 stars	$12.45 -2.1%	$9.50 -23.7%	+113.5%	$206.06M	$218.53M	N/A	562	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCAT) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Competitors

HCAT vs. NRC, EVH, CTEV, AMWL, and OPRX

How does Health Catalyst compare to National Research?

Summary

How does Health Catalyst compare to Evolent Health?

Summary

How does Health Catalyst compare to Claritev?

Summary

How does Health Catalyst compare to American Well?

Summary

How does Health Catalyst compare to OptimizeRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Catalyst (HCAT) Competitors

HCAT vs. NRC, EVH, CTEV, AMWL, and OPRX

How does Health Catalyst compare to National Research?

Does the media prefer NRC or HCAT?

Which has better valuation and earnings, NRC or HCAT?

Which has more volatility & risk, NRC or HCAT?

Do insiders and institutionals have more ownership in NRC or HCAT?

Do analysts prefer NRC or HCAT?

Is NRC or HCAT more profitable?

Summary

How does Health Catalyst compare to Evolent Health?

Do analysts recommend EVH or HCAT?

Which has better earnings and valuation, EVH or HCAT?

Does the media refer more to EVH or HCAT?

Which has more risk & volatility, EVH or HCAT?

Is EVH or HCAT more profitable?

Do insiders & institutionals believe in EVH or HCAT?

Summary

How does Health Catalyst compare to Claritev?

Which has stronger valuation and earnings, HCAT or CTEV?

Does the media favor HCAT or CTEV?

Do institutionals and insiders have more ownership in HCAT or CTEV?

Which has more volatility & risk, HCAT or CTEV?

Do analysts recommend HCAT or CTEV?

Is HCAT or CTEV more profitable?

Summary

How does Health Catalyst compare to American Well?

Which has better valuation & earnings, HCAT or AMWL?

Is HCAT or AMWL more profitable?

Do insiders and institutionals have more ownership in HCAT or AMWL?

Which has more volatility and risk, HCAT or AMWL?

Do analysts recommend HCAT or AMWL?

Does the media favor HCAT or AMWL?

Summary

How does Health Catalyst compare to OptimizeRx?

Does the media prefer OPRX or HCAT?

Which has stronger earnings and valuation, OPRX or HCAT?

Do insiders & institutionals hold more shares of OPRX or HCAT?

Do analysts recommend OPRX or HCAT?

Which has more risk & volatility, OPRX or HCAT?

Is OPRX or HCAT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools